Role of protein kinase C in podocytes and development of glomerular damage in diabetic nephropathy

Frontiers in Endocrinology

Volumn 5, Issue NOV, 2014, Pages

  Teng, Beina ^a   Duong, Michelle ^a   Tossidou, Irini ^a   Yu, Xuejiao ^a   Schiffer, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Diabetic podocytopathy; Effacement; Glomerulosclerosis; Nephrin endocytosis; Proteinuria

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; P CADHERIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

APOPTOSIS; CELL CYCLE PARAMETERS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HUMAN; METABOLIC REGULATION; PATHOGENESIS; PODOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION;

EID: 84920111614     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00179     Document Type: Review

References (71)

1. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia (2008) 51:1347-55. doi: 10.1007/s00125-008-1051-7
2. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia (1999) 42:1341-4. doi:10.1007/s001250051447
3. Susztak K, RaffAC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes (2006) 55:225-33. doi:10.2337/diabetes.55.01.06.db05-0894
4. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes (2007) 56:2155-60. doi:10.2337/db07-0019
5. Verzola D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, et al. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int (2007) 72:1262-72. doi:10.1038/sj.ki.5002531
6. White KE, Bilous RW, Marshall SM, El NM, Remuzzi G, Piras G, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 51:3083-9. doi:10.2337/diabetes.51.10.3083
7. Benzing T. Signaling at the slit diaphragm. J Am Soc Nephrol (2004) 15:1382-91. doi:10.1097/01.ASN.0000130167.30769.55
8. Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis (2011) 58:637-46. doi:10.1053/j.ajkd.2011.03.035
9. Li J, Gobe G. Protein kinase C activation and its role in kidney disease. Nephrology (Carlton) (2006) 11:428-34. doi:10.1111/j.1440-1797.2006.00673.x
10. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev (2008) 88:1341-78. doi:10.1152/physrev.00034.2007
11. Pears C, Stabel S, Cazaubon S, Parker PJ. Studies on the phosphorylation of protein kinase C-alpha. Biochem J (1992) 283(Pt 2):515-8.
12. Dietrich A, Rose-John S, Marks F. Expression of the kinase domain of mouse protein kinase C in E. coli. Biochem Int (1989) 19:163-72.
13. Cazaubon SM, Parker PJ. Identification of the phosphorylated region responsible for the permissive activation of protein kinase C. J Biol Chem (1993) 268:17559-63.
14. Borner C, Filipuzzi I, Wartmann M, Eppenberger U, Fabbro D. Biosynthesis and posttranslational modifications of protein kinase C in human breast cancer cells. J Biol Chem (1989) 264:13902-9.
15. Liu WS, Heckman CA. The sevenfold way of PKC regulation. Cell Signal (1998) 10:529-42. doi:10.1016/S0898-6568(98)00012-6
16. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A (1992) 89:11059-63. doi:10.1073/pnas.89.22.11059
17. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res (2004) 53:131-42.
18. Meinhardt G, Roth J, Totok G. Protein kinase C activation modulates pro-and anti-apoptotic signaling pathways. Eur J Cell Biol (2000) 79:824-33. doi:10.1078/0171-9335-00100
19. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol (2003) 14:S241-5. doi:10.1097/01.ASN.0000077410.66390.0F
20. Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes (2004) 53:2101-9. doi:10.2337/diabetes.53.8.2101
21. Menne J, Meier M, Park JK, Boehne M, Kirsch T, Lindschau C, et al. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int (2006) 70:1456-62. doi:10.1038/sj.ki.5001830
22. Tossidou I, Teng B, Menne J, Shushakova N, Park JK, Becker JU, et al. Podocytic PKC-alpha is regulated in murine and human diabetes and mediates nephrin endocytosis. PLoS One (2010) 5:e10185. doi:10.1371/journal.pone.0010185
23. Quack I, Woznowski M, PotthoffSA, Palmer R, Konigshausen E, Sivritas S, et al. PKC alpha mediates beta-arrestin2-dependent nephrin endocytosis in hyperglycemia. J Biol Chem (2011) 286:12959-70. doi:10.1074/jbc. M110.204024
24. Guo G, Morrison DJ, Licht JD, Quaggin SE. WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. J Am Soc Nephrol (2004) 15:2851-6. doi:10.1097/01.ASN.0000143474.91362.C4
25. Wagner N, Wagner KD, Xing Y, Scholz H, Schedl A. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. J Am Soc Nephrol (2004) 15:3044-51. doi:10.1097/01.ASN.0000146687.99058.25
26. Wang SX, Mene P, Holthofer H. Nephrin mRNA regulation by protein kinase C. J Nephrol (2001) 14:98-103.
27. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int (2004) 65:2193-200. doi:10.1111/j.1523-1755.2004.00636.x
28. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui P, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia (2002) 45:1572-6. doi:10.1007/s00125-002-0946-y
29. Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol (2000) 279:L429-38.
30. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, et al. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes (2000) 49:87-93. doi:10.2337/diabetes.49.1.87
31. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes (2004) 53:2921-30. doi:10.2337/diabetes.53.11.2921
32. Meier M, King GL. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med (2000) 5:173-85. doi:10.1177/1358836X0000500307
33. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 272:728-31. doi:10.1126/science.272.5262.728
34. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest (1997) 100:115-26. doi:10.1172/JCI119503
35. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J (2000) 14:439-47.
36. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes (2003) 52:512-8. doi:10.2337/diabetes.52.2.512
37. Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, Gueler F, et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes (2007) 56:346-54. doi:10.2337/db06-0891
38. Menne J, Shushakova N, Bartels J, Kiyan Y, Laudeley R, Haller H, et al. Dual inhibition of classical protein kinase C-alpha and protein kinase C-beta isoforms protects against experimental murine diabetic nephropathy. Diabetes (2013) 62:1167-74. doi:10.2337/db12-0534
39. Kang N, Alexander G, Park JK, Maasch C, Buchwalow I, Luft FC, et al. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int (1999) 56:1737-50. doi:10.1046/j.1523-1755.1999.00725.x
40. Whiteside CI, Dlugosz JA. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol (2002) 282:F975-80. doi:10.1152/ajprenal.00014.2002
41. Meier M, Menne J, Park JK, Holtz M, Gueler F, Kirsch T, et al. Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J Am Soc Nephrol (2007) 18:1190-8. doi:10.1681/ASN.2005070694
42. Henrique D, Schweisguth F. Cell polarity: the ups and downs of the Par6/aPKC complex. Curr Opin Genet Dev (2003) 13:341-50. doi:10.1016/S0959-437X(03)00077-7
43. Macara IG. Par proteins: partners in polarization. Curr Biol (2004) 14:R160-2. doi:10.1016/j.cub.2004.01.048
44. Suzuki A, Yamanaka T, Hirose T, Manabe N, Mizuno K, Shimizu M, et al. Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol (2001) 152:1183-96. doi:10.1083/jcb.152.6.1183
45. Hartleben B, Schweizer H, Lubben P, Bartram MP, Moller CC, Herr R, et al. Neph-Nephrin proteins bind the Par3-Par6-atypical protein kinase C (aPKC) complex to regulate podocyte cell polarity. J Biol Chem (2008) 283:23033-8. doi:10.1074/jbc. M803143200
46. Huber TB, Hartleben B, Winkelmann K, Schneider L, Becker JU, Leitges M, et al. Loss of podocyte aPKClambda/iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol (2009) 20:798-806. doi:10.1681/ASN.2008080871
47. Satoh D, Hirose T, Harita Y, Daimon C, Harada T, Kurihara H, et al. aPKClambda maintains the integrity of the glomerular slit diaphragm through trafficking of nephrin to the cell surface. J Biochem (2014) 156:115-28. doi:10.1093/jb/mvu022
48. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes (2003) 52:1023-30. doi:10.2337/diabetes.52.4.1023
49. Sajan MP, Farese RV. Insulin signalling in hepatocytes of humans with type 2 diabetes: excessive production and activity of protein kinase C-iota (PKC-iota) and dependent processes and reversal by PKC-iota inhibitors. Diabetologia (2012) 55:1446-57. doi:10.1007/s00125-012-2477-5
50. Hartleben B, Widmeier E, Suhm M, Worthmann K, Schell C, Helmstadter M, et al. aPKClambda/iota and aPKCzeta contribute to podocyte differentiation and glomerular maturation. J Am Soc Nephrol (2013) 24:253-67. doi:10.1681/ASN.2012060582
51. Worthmann K, Leitges M, Teng B, Sestu M, Tossidou I, Samson T, et al. Def-6, a novel regulator of small GTPases in podocytes, acts downstream of atypical protein kinase C (aPKC) lambda/iota. Am J Pathol (2013) 183:1945-59. doi:10.1016/j.ajpath.2013.08.026
52. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int (1992) 42:1457-61. doi:10.1038/ki.1992.441
53. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl (2000) 77:S104-12. doi:10.1046/j.1523-1755.2000.07717.x
54. Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med (2004) 36:65-70. doi:10.1038/emm.2004.9
55. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun (2002) 290:177-84. doi:10.1006/bbrc.2001.6138
56. Janknecht R, Ernst WH, Houthaeve T, Nordheim A. C-terminal phosphorylation of the serum-response factor. Eur J Biochem (1993) 216:469-75. doi:10.1111/j.1432-1033.1993.tb18165.x
57. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem (1995) 270:16483-6. doi:10.1074/jbc.270.28.16483
58. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol (1997) 9:240-6. doi:10.1016/S0955-0674(97)80068-3
59. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem (1996) 271:3877-83.
60. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (1991) 266:11947-54.
61. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int (2010) 77:989-99. doi:10.1038/ki.2010.64
62. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol (2007) 18:2094-104. doi:10.1681/ASN.2006010075
63. Tossidou I, Starker G, Kruger J, Meier M, Leitges M, Haller H, et al. PKC-alpha modulates TGF-beta signaling and impairs podocyte survival. Cell Physiol Biochem (2009) 24:627-34. doi:10.1159/000257518
64. Chuang LY, Guh JY, Liu SF, Hung MY, Liao TN, Chiang TA, et al. Regulation of type II transforming-growth-factor-beta receptors by protein kinase C iota. Biochem J (2003) 375:385-93. doi:10.1042/BJ20030522
65. Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol (2000) 11:1-8.
66. Xu ZG, Ryu DR, Yoo TH, Jung DS, Kim JJ, Kim HJ, et al. P-Cadherin is decreased in diabetic glomeruli and in glucose-stimulated podocytes in vivo and in vitro studies. Nephrol Dial Transplant (2005) 20:524-31. doi:10.1093/ndt/gfh642
67. Hendriksen J, Jansen M, Brown CM, van der Velde H, van HM, Galjart N, et al. Plasma membrane recruitment of dephosphorylated beta-catenin upon activation of the Wnt pathway. J Cell Sci (2008) 121:1793-802. doi:10.1242/jcs.025536
68. Kato H, Gruenwald A, Suh JH, Miner JH, Barisoni-Thomas L, Taketo MM, et al. Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem (2011) 286:26003-15. doi:10.1074/jbc. M111.223164
69. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol (2009) 20:1997-2008. doi:10.1681/ASN.2009010019
70. Gwak J, Cho M, Gong SJ, Won J, Kim DE, Kim EY, et al. Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway. J Cell Sci (2006) 119:4702-9. doi:10.1242/jcs.03256
71. Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood (2009) 113:1513-21. doi:10.1182/blood-2008-05-157040